问题 › 我的业务实际价值是多少？ › 医疗服务提供商
估值主要看是否有每 episode 成本数据来为归因人头的下行风险定价，而非面板规模。 这个问题在医疗服务提供商这里不是通用版本。已对 38,000 名归因人头承担下行风险，却缺少定价所需的每 episode 成本数据——忽略该数据的答案必然错误。分析必须从付款人组合和面板规模入手，而非从收入开始。
估值主要看是否有每 episode 成本数据来为归因人头的下行风险定价，而非面板规模。 这个问题在医疗服务提供商这里不是通用版本。已对 38,000 名归因人头承担下行风险，却缺少定价所需的每 episode 成本数据——忽略该数据的答案必然错误。分析必须从付款人组合和面板规模入手，而非从收入开始。
经营者往往将估值视为应用于每提供商贡献的倍数。买家则判断在现有付款人组合和基于价值的合同下，该贡献在他们所有权下能保留多少，因此两家面板规模相同的提供商售价可能大相径庭。
驱动因素一致：归因人头中付款人组合的集中度、面板规模中锁定在 recurring 基于价值条款的比例、结果对医疗总监的依赖程度，以及未来几年能否在缺乏更好数据的情况下守住每 episode 成本。这些因素对倍数的影响，超过每提供商贡献每增加一个点对基数的影响。
这意味着实际问题通常不是面板值多少，而是哪一项在压低倍数，以及能否在出售前可用时间内修复。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 你已在基于价值的合同下对 38,000 名归因人头承担下行风险，而每 episode 成本数据从未清理或标准化。
✓ 每提供商贡献的很大一部分依赖医疗总监持有的关系。
✓ 面板收入主要绑定在缺少每 episode 成本数据的付款人安排上，这些安排难以维持条款。
通常会让情况更糟的做法。 出售前一年优化每提供商贡献，却不触碰每 episode 成本可见性和付款人组合问题，这通常比修复其中一项增加的价值更少。
It is for you if you run or finance a healthcare provider and you are within a few years of a transaction and have never had the earnings normalised. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
按行业找范围很容易，但这是答案中最没用的部分。你落在范围内的位置，由集中度、复购性、所有者依赖和利润可防御性决定。
若目标是移动倍数，需要两到三年，因为 recurring 收入和降低所有者依赖需要这么长时间才能在数字中显现。
取决于买家。财务买家为 durable 现金流付费；战略买家为业务对其自身位置的影响付费。知道你在为哪类买家准备，会改变该修复的内容。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית